Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell Lung Cancer in a randomised phase II study

European Journal of Cancer

Volumn 28, Issue 1, 1992, Pages 96-100

  Postmus, P E ^a   Splinter, T A W ^b   Palmen, F M L H G ^c   Carney, D N ^d   Festen, J ^e   Burghouts, J Th W ^f   Vendrik, C ^g   Roozendaal, K ^h   Planting, A S T ^b   Quoix, E ⁱ   van Zandwijk, N ^j   Rinaldi, M ^k   Giaccone, G ^l   Koolen, M ^m   Miech, G ⁿ   van de Lichte, J L ^o   Kirkpatrick, A ^p   Evrard, D ^p   Dalesio, O ^j  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ST ELISABETH HOSPITAL   (Netherlands)

^d MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Grootzie kengasthuis ^*  (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ Daniël den Hoed Kliniek ^*  (France)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l MOLINETTE HOSPITAL   (Italy)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ Maria Hospital TIlburg   (Netherlands)

^o CENTRE HOSPITALIER DE MULHOUSE   (France)

^p EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG EVALUATION; ETOPOSIDE; FEMALE; HUMAN; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGE; RANDOM ALLOCATION; TIME FACTORS; VINCRISTINE;

EID: 0026518302     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(92)90394-H     Document Type: Article

References (22)

1. Small-cell lung cancer. A curable disease
2. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer
3. Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma
4. Early clinical studies with cis-diammine-I,I-cyclobutane dicarboxylate platinum. II
5. A prospective trial of VM26 and carboplatinum in the treatment of small cell lung cancer (abstr.)
6. Ifosfamide in the treatment of bronchial carcinoma
7. EORTC 08825: induction versus induction plus maintenance chemotherapy in small cell lung cancer. Definitive evaluation
8. Handbook for Reporting Results of Cancer Treatment
9. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy
10. Acute and cumulative effects of carboplatin on renal function
11. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study
12. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for limited stage small cell lung carcinoma of the bronchus
13. Etoposide, carboplatin, cyclophosphamide and vincristine (ECCO) in previously untreated patients with small cell lung cancer
14. Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small-cell lung cancer
15. Carboplatin dosage: prospective evaluation of a simple formula based on renal function
16. A double-blind placebo-controlled study with GM-CSF during chemotherapy for ovarian cancer
17. Etoposide and cisplatin: an effective treatment for relapse in small cell lung cancer
18. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung
19. Chemotherapy in small cell lung cancer: a consensus report
20. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer
21. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer